CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) reached a new 52-week high during mid-day trading on Monday. The company traded as high as $99.00 and last traded at $89.78, with a volume of 372,391 shares. The stock had previously closed at $74.40.
Analysts Set New Price Targets
Several brokerages recently issued reports on CGON. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Thursday, October 15th. Royal Bank Of Canada decreased their price objective on CG Oncology from $81.00 to $79.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Piper Sandler increased their price objective on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Finally, Wall Street Zen raised CG Oncology from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.11.
Read Our Latest Research Report on CGON
CG Oncology Price Performance
The company’s 50 day moving average is $68.04 and its 200 day moving average is $66.54. The stock has a market cap of $7.43 billion, a price-to-earnings ratio of -28.85 and a beta of 0.35.
CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.19. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million. CG Oncology had a negative return on equity of 24.58% and a negative net margin of 3,851.09%. Sell-side analysts predict that CG Oncology, Inc. will post -3.00 earnings per share for the current year.
Insider Activity
In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the sale, the director owned 1,000 shares of the company’s stock, valued at $62,060. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.80% of the stock is owned by company insiders.
Institutional Trading of CG Oncology
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fiduciary Financial Advisors acquired a new position in shares of CG Oncology during the 2nd quarter valued at about $28,000. Manchester Capital Management LLC lifted its stake in shares of CG Oncology by 2,895.5% in the 3rd quarter. Manchester Capital Management LLC now owns 659 shares of the company’s stock valued at $47,000 after purchasing an additional 637 shares in the last quarter. Covestor Ltd lifted its stake in shares of CG Oncology by 72.6% in the 3rd quarter. Covestor Ltd now owns 770 shares of the company’s stock valued at $55,000 after purchasing an additional 324 shares in the last quarter. Fifth Third Bancorp acquired a new position in shares of CG Oncology in the 1st quarter valued at about $74,000. Finally, GAMMA Investing LLC grew its holdings in shares of CG Oncology by 47.9% during the 3rd quarter. GAMMA Investing LLC now owns 1,081 shares of the company’s stock worth $77,000 after purchasing an additional 350 shares during the period. 26.56% of the stock is currently owned by hedge funds and other institutional investors.
CG Oncology Company Profile
CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.
Recommended Stories
- Five stocks we like better than CG Oncology
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
